Overview: SCA17 TestIntroduction: The SCA17 Test tests for TBP gene mutations to diagnose spinocerebellar ataxia type 17, causing coordination issues or cognitive decline, aiding in genetic diagnosis. Affecting 1 in 100,000 people, SCA17 poses diagnostic challenges due to varied symptoms. Following 2023 National Organization for Rare Disorders (NORD) guidelines, it uses PCR/fragment analysis for high accuracy, supporting molecular pathology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in neurology.
Other Names: TBP Mutation Test, SCA17 Gene Assay.
FDA Status: Laboratory-developed test (LDT), meeting pathology standards for diagnostic reliability.
Historical Milestone: SCA17 testing began in the 1990s with research by Koide, who identified the mutation. PCR/fragment analysis advancements by Applied Biosystems improved detection, surpassing earlier linkage analysis.
Purpose: Detects TBP mutation status to diagnose spinocerebellar ataxia type 17, guides supportive care, and evaluates patients with coordination issues, aiming to manage symptoms.
Test Parameters: TBP mutation status
Pretest Condition: No special preparation required. Collect whole blood, buccal swab, or saliva. Report history of neurological issues.
Specimen: Whole Blood (EDTA, 3-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL); 4 mL whole blood in EDTA tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document coordination issues or cognitive decline. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., dementia), and sample collection risks.
Procedural Considerations: Uses PCR/fragment analysis to detect mutations, requiring labs with thermal cyclers. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive mutation confirms SCA17, guiding care. Early management might slow progression, while untreated cases lead to disability. Normal results may require other tests.
Specialist Consultation: Consult a neurologist or genetic counselor for interpretation.
Additional Supporting Tests: MRI, cognitive testing, or genetic panel to confirm diagnosis.
Test Limitations: Specific to TBP; correlation with clinical status needed. False negatives possible with other mutations.
References: NORD Guidelines, 2023; Nature Genetics, Koide R, 2022.
